6th Annual Pharma Packaging and Labeling USA 201426-27 February 2014, Philadelphia, USA
The 6th year of a truly successful and respected Pharma Packaging and Labeling event is rolling back into town with this year expected to be bigger than ever.
With key legislation on the horizon in California and the counterfeiting market now worth millions of dollars as well as sustainability and green packaging in demand, the need for this event is heightened.
We aim to bring you more compelling speakers talking about the subjects that matter to you. Following extensive research into the market we have been able identify key themes to discuss, issues to debate and people you want to meet all under one roof.
This outstanding event will provide a fantastic opportunity for exhibitors to promote their products and services to senior level decision makers from the region. Exhibition spaces are filling up due to the success of last year’s event as well as the global reputation of this world-renowned series.
Pharma Packaging and Labeling 2014 aims to target specific areas of the market in an interesting and insightful manner.
Rondo Pak would like to welcome all attendees of Pharma Packaging and Labeling to their drink reception taking place at the end of day one, on the 26th of February.
Germany-based Boehringer Ingelheim has entered an exclusive global licence and development collaboration with CureVac to develop lung cancer immunotherapy.
India-based Sun Pharma has signed an exclusive worldwide licensing agreement with US-based Merck for its investigational therapeutic antibody candidate, tildrakizumab (MK-3222).
France-based Sanofi has partnered with US-based MyoKardia to discover and develop targeted therapeutics to treat patients with genetic heart disease.
AstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Movantik (naloxegol) tablets C-II to treat opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
Researchers at the University of Warwick in UK have discovered a new drug target, Kir7.1, for postpartum haemorrhage (PPH) in women.